Human PD-L1/B7-H1 DuoSet ELISA, 15 Plate

• Reactivity: Hu
• Applications: ELISA
• Conjugate: Biotin

Human PD-L1/B7-H1 DuoSet ELISA, 15 Plate Summary

• Source: N/A
• Assay Type: Solid Phase Sandwich ELISA
• Inter-Assay: See PDF Datasheet for details
• Intra-Assay: See PDF Datasheet for details
• Spike Recovery: See PDF Datasheet for details
• Sample Volume: See PDF Datasheet for details
• Gene: CD274

Applications/Dilutions

• Dilutions:
  • ELISA
• Application Notes: No significant interference observed with available related molecules.

Packaging, Storage & Formulations

• Storage: Store the unopened product at 2 - 8 °C. Do not use past expiration date.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Human PD-L1/B7-H1 DuoSet ELISA, 15 Plate

• Avelumab
• B7-H
• B7H1
• B7-H1
• B7H1PDCD1L1
• CD274 antigenMGC142294
• CD274 molecule
• CD274
• PDCD1L1
• PDCD1LG1
• PDCD1LG1MGC142296
• PDL1
• PD-L1
• PD-L1B7 homolog 1
• PDL1PDCD1 ligand 1
• programmed cell death 1 ligand 1
• Programmed death ligand 1

Background

PD-L1, also known as B7-H1 and CD274, is an approximately 65 kDa transmembrane glycoprotein in the B7 family of immune regulatory molecules. PD-L1 is expressed on inflammatory-activated immune cells including macrophages, T cells, and B cells, keratinocytes, enothelial and intestinal epithelial cells, as well as a variety of carcinomas and melanoma. PD-L1 binds to T cell B7-1/CD80 and PD-1. It suppresses T cell activation and proliferation and induces the apoptosis of activated T cells. It plays a role in the development of immune tolerance by promoting T cell anergy and enhancing regulatory T cell development. PD-L1 favors the development of anti-inflammatory IL-10 and IL-22 producing dendritic cells and inhibits the development of Th17 cells. In cancer, PD-L1 provides resistance to T cell mediated lysis, enhances EMT, and enhances the tumorigenic function of Th22 cells.

Publications for PD-L1 (DY156)(9)

Publications using DY156

• Miladinov, M;Rosic, J;Eric, K;Guzonjic, A;Jelenkovic, J;Bogavac-Stanojevic, N;Dimitrijevic, I;Kotur-Stevuljevic, J;Barisic, G; Analysis of the Prognostic Potential of Schlafen 11, Programmed Death Ligand 1, and Redox Status in Colorectal Cancer Patients International journal of molecular sciences 2023-10-11 [PMID: 37894765] (Human)
• K Krueger, Z Mayer, M Kottmaier, M Gerckens, S Boeck, P Luppa, S Holdenried Robust Preanalytical Performance of Soluble PD-1, PD-L1 and PD-L2 Assessed by Sensitive ELISAs in Blood Biomedicines, 2022-10-11;10(10):. 2022-10-11 [PMID: 36289796] (Human)
• K Krueger, Z Mayer, M Gerckens, S Boeck, P Luppa, S Holdenried High Quality Performance of Novel Immunoassays for the Sensitive Quantification of Soluble PD-1, PD-L1 and PD-L2 in Blood Biomedicines, 2022-09-26;10(10):. 2022-09-26 [PMID: 36289665] (Human)
• M Roksandic, A Klisic, V Ceriman, J Kotur Stev, K Savic Vujo, D Mirkov, M Gajic, B Ilic, N Dimic, N Samardzic, D Jovanovic Oxidative stress and inflammation parameters-novel biomarkers for idiopathic pulmonary fibrosis European review for medical and pharmacological sciences, 2022-02-01;26(3):927-934. 2022-02-01 [PMID: 35179759] (Human)
• G Larrinaga, JD Solano-Itu, P Errarte, M Unda, A Loizaga-Ir, A Pérez-Fern, E Echevarría, A Asumendi, C Manini, JC Angulo, JI López Soluble PD-L1 Is an Independent Prognostic Factor in Clear Cell Renal Cell Carcinoma Cancers, 2021-02-07;13(4):. 2021-02-07 [PMID: 33562338] (Human)
• C Voisin, G Cauchois, L Reppel, C Laroye, L Louarn, C Schenowitz, P Sonon, I Poras, V Wang, E D Carosell, N Benkirane-, P Moreau, N Rouas-Frei, D Bensoussan, C Huselstein Are the Immune Properties of Mesenchymal Stem Cells from Wharton's Jelly Maintained during Chondrogenic Differentiation? J Clin Med, 2020-02-04;9(2):. 2020-02-04 [PMID: 32033151] (Human)
• Jovanovic D, Roksandic Milenkovic M, Kotur Stevuljevic J, Markovic J, Ceriman V, Kontic M, Skodric Trifunovic V Membrane PD-L1 expression and soluble PD-L1 plasma levels in idiopathic pulmonary fibrosis-a pilot study. J Thorac Dis, 2018-12-01;10(12):6660-6669. 2018-12-01 [PMID: 30746211] (Human)
• S Kruger, ML Legenstein, V Rösgen, M Haas, DP Modest, CB Westphalen, S Ormanns, T Kirchner, V Heinemann, S Holdenried, S Boeck Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer Oncoimmunology, 2017-03-31;6(5):e1310358. 2017-03-31 [PMID: 28638732] (Human)
• Mesenchymal Stromal Cell Secretion of Programmed Death-1 Ligands Regulates T Cell Mediated Immunosuppression Stem Cells, 2016-10-26;0(0):. 2016-10-26 [PMID: 27671847] (Human)

FAQs for PD-L1 (DY156). (Showing 1 - 1 of 1 FAQs).

1. wondering what the difference is between your quantikine and duo set elisas?
   • Usually the duosets do not have the entire kit such as plates and buffers, whereas the other kits are complete.

Bioinformatics

• Gene Symbol: CD274